CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
应对多发性骨髓瘤的经济负担：CAR-T 与双特异性抗体疗法成本效益的洞见
英文原题：Navigating the Economic Burden of Multiple Myeloma: Insights into Cost-effectiveness of CAR-T and Bispecific Antibody Therapies.
查看英文原题
Navigating the Economic Burden of Multiple Myeloma: Insights into Cost-effectiveness of CAR-T and Bispecific Antibody Therapies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
综述目的：多发性骨髓瘤是一种慢性恶性肿瘤，随着治疗选择不断发展，临床医师和研究者有必要了解疗法的经济负担和成本效益。 近期发现：本文回顾近期获批用于骨髓瘤的双特异性抗体和CAR-T 疗法及其直接和间接成本，并与当前治疗方案进行成本比较。我们认为，根据国家和所采用的模型，在较早治疗线次使用CAR-T 等更有效疗法可能更具成本效益。仍需进一步研究更好地了解双特异性抗体的成本效益，包括与CAR-T 疗法开展头对头比较。
展开英文摘要原文
PURPOSE OF REVIEW: Multiple myeloma is a chronic malignancy and with evolving treatment options, understanding the economic burden and cost-effectiveness of therapies is crucial for clinicians and researchers. RECENT FINDINGS: In this, we review the recent approval of Bispecific antibodies and CAR-T for myeloma and their cost implications, including direct and indirect costs.
We compare this to current regimens and provide cost comparisons in this review.
We conclude that the use of more effective therapies such as CAR-T in earlier lines of therapies may be more cost-effective depending on the country and model used.
Further studies are essential to better understand the cost-effectiveness of bispecific antibodies including head-to-head comparisons to CAR-T therapy.
论文信息
- 作者
- Keesari PR、Samuels D、Vegivinti CTR、Pulakurthi YS、Kudithi R、Dhar M、Janakiram M
- 第一作者单位
- Department of Internal Medicine, Staten Island University Hospital, Staten Island, NY, USA.United States
- 通讯作者单位
- Division of Myeloma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA, 91010, USA. mjanakiram@coh.org.United States
- 文献类型
- 综述
- 期刊
- Current hematologic malignancy reports2025 Jan 4
- 原文标识
- PubMed 39754658 · DOI 10.1007/s11899-024-00748-5
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →